BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

N/A
indicator

Nifty500 Healthcare Index

1D
1M
3M
6M
1Y
5Y
empty graph

Nifty500 Healthcare Index Performance

Day's Range

Low

₹21,290.30

High

₹21,419.15

52 Week Range

Low

₹17,164.05

High

₹21,470.95

Previous Close ₹21,363.45
Day's Range ₹21,290.30 - ₹21,419.15
Open ₹21,381.60
52 Week Range ₹17,164.05 - ₹21,470.95
Volume 3,29,76,082

Nifty500 Healthcare Index Companies

Company Name LTP (₹) Change (₹) Sector
Cipla Ltd. 1432.60 Arrow -9.00 (-0.62%) Healthcare
Dr. Reddy's Laboratories Ltd. 1211.50 Arrow -11.60 (-0.95%) Healthcare
Lupin Ltd. 2508.90 Arrow 30.40 (1.23%) Healthcare
Torrent Pharmaceuticals Ltd. 5039.60 Arrow 34.20 (0.68%) Healthcare
Abbott India Ltd. 28755.00 Arrow 480.00 (1.70%) Healthcare
Glaxosmithkline Pharmaceuticals Ltd. 2503.40 Arrow 20.30 (0.82%) Healthcare
Pfizer Ltd. 4592.10 Arrow 14.20 (0.31%) Healthcare
Apollo Hospitals Enterprise Ltd. 8893.00 Arrow -12.00 (-0.13%) Healthcare
Ipca Laboratories Ltd. 1798.90 Arrow -39.70 (-2.16%) Healthcare
Neuland Laboratories Ltd. 18945.00 Arrow -4.00 (-0.02%) Healthcare

All Indices

Index Name Market Value 52W High 52W Low
Nifty 50 24179.75 26373.20 22182.55
Nifty IT 28991.75 40301.40 25699.10
Nifty Next 50 72585.2 73141.05 59896.10
NIFTY50 USD Index 8715.75 10443.40 8132.40
Nifty Bank 57913.65 61764.85 49954.85
NIFTY Midcap 100 62956.8 63183.35 52032.85
Nifty 500 23338.6 24144.20 20385.65
Nifty Midcap 50 18093.15 18114.45 14804.55
Nifty 100 25244.4 26975.15 22720.45
Nifty FMCG 48829.9 58485.05 45334.15

Latest News

Jul
21
2026
EQUITY Posted on Jul 21st 2026

Glenmark Pharmaceuticals informs about press release

Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.

Read More
Jul
21
2026
EQUITY Posted on Jul 21st 2026

Lupin informs about acquisition

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, Lupin has informed that Lupin Inc. U.S.A., wholly owned subsidiary of the Company, has entered into a licensing agreement to grant an exclusive perpetual license for two of its oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), to Kaveri Therapeutics, Inc. U.S.A. (‘Kaveri’), in exchange for an 82.2% equity stake (Common Shares) in Kaveri. The details required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI Master Circular dated January 30, 2026 (reference no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026), along with other applicable circulars, are set out in Annexure I. A press release regarding this arrangement is enclosed.

The above information is a part of company’s filings submitted to BSE.

Read More
Jul
20
2026
EQUITY Posted on Jul 20th 2026

Blue Jet Healthcare informs about press release

Blue Jet Healthcare has informed that the company has been awarded with Silver Medal by EcoVadis for its outstanding sustainability management practices in areas such as Environment, Labor and Human Rights, Ethics and Sustainable Procurement. In this regard, it has attached press release issued by the company.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
20
2026
EQUITY Posted on Jul 20th 2026

Acutaas Chemicals informs about conference call

Acutaas Chemicals has informed that pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, an Earnings Conference Call has been organised on Friday, July 24, 2026 at 4.00 PM (IST) to discuss the Unaudited Financial Results of the Company for the first quarter ended on June 30, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
20
2026
EQUITY Posted on Jul 20th 2026

Ajanta Pharma informs about conference call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Ajanta Pharma has informed that it enclosed the schedule of Earnings Conference Call to be held on 30th July 2026, post Board meeting.
The above information is a part of company’s filings submitted to BSE. 
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Frequently Asked Questions

What is the Previous Close of NFT500HEALTH index?

The previous close of NFT500HEALTH index is ₹21411.55 as of 2026-07-21.

The total volume of NFT500HEALTH index is 32976082.00 as of 2026-07-21.

The percentage change in value of NFT500HEALTH index is 0.23% as of 2026-07-21.

The absolute increase in NFT500HEALTH index value since the previous trading day is ₹48.1 as of 2026-07-21.

A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.

View More

People Also Ask

What defines the Nifty 500 Healthcare Index?

The Nifty 500 Healthcare Index is a sectoral index that tracks selected healthcare companies from the Nifty 500 universe. It represents listed businesses across healthcare delivery, pharmaceuticals, diagnostics, biotechnology, medical services, and related segments.

Companies are selected from healthcare-sector stocks within the Nifty 500 universe based on NSE Indices' methodology and industry classification. The index is reviewed periodically in accordance with the index maintenance methodology.

The Nifty 500 Healthcare Index is calculated using the free-float market capitalisation method. This approach considers only publicly available shares while assigning weights to eligible healthcare companies within the index.

The Nifty 500 Healthcare Index includes companies from pharmaceuticals, hospitals, diagnostics, biotechnology, healthcare services, medical equipment, and related healthcare businesses listed within the broader Nifty 500 universe.

Yes, hospitals, diagnostics, and pharmaceutical companies may be part of the Nifty 500 Healthcare Index if they meet the index provider’s eligibility rules. The index is designed to capture different areas of India’s healthcare sector.

The Nifty 500 Healthcare Index measures the performance of healthcare-sector companies included in the Nifty 500 universe. It reflects the market performance of listed companies engaged in areas such as pharmaceuticals, hospitals, diagnostics, biotechnology, medical equipment, and other healthcare-related businesses.

The Nifty 500 Healthcare Index is reviewed and rebalanced periodically in accordance with NSE Indices' index maintenance methodology. The review helps ensure that the index continues to reflect eligible healthcare companies within the Nifty 500 universe.

View More
Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore